Eli Lilly Stock News

The insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.

Eli Lilly and Company announced promising results for its weight loss drug Zepbound, indicating its potential as a treatment for sleep apnea. The drug demonstrated effectiveness in reducing the severi

A late-stage trial of Eli Lilly's weight loss drug Zepbound showed promising results in treating sleep apnea symptoms in obese adults, the company announced Wednesday, the latest findings suggesting p

Eli Lilly And Co   (NYSE:LLY) stock was last seen up 2.8% at $767.65, after the pharmaceutical giant said data from two late-stage trials showed its weight loss drug Mounjaro helped reduce irregular

The U.S. Food and Drug Administration website showed that most doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be available in limited amounts through the second quarte

The Eli Lilly and Co (NYSE:LLY) weightloss drug Tirzepatide, known as Zepbound and Mounjaro, has also been shown in two trials to help improve the symptoms of sleep apnea. Tirzepatide "meaningfully

Eli Lilly's weight-loss drug succeeded in two late-stage trials testing it in patients with obstructive sleep apnea, the company said on Wednesday.

Eli Lilly & Co. LLY, -0.54% said Wednesday that two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced sleep a

The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year.

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

In the closing of the recent trading day, Eli Lilly (LLY) stood at $749.26, denoting a -0.2% change from the preceding trading day.

Atossa Therapeutics Inc (NASDAQ:ATOS) and its research partner Quantum Leap Healthcare Collaborative announced the initiation of a new study evaluating Atossa's lead drug candidate (Z)-endoxifen in co

A staggering $1 trillion could be the annual cost to the US healthcare system if 40% of Americans with obesity begin treatment with GLP-1 drugs at current prices, according to Dr Jonathan Gruber, th

CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.